micro-community-banner
 
  • Saved
Enhancing Patient Outcomes in gMG Through Shared Decision-Making

Shared decision-making (SDM) is a patient-centered healthcare model fostering collaboration between patients, caregivers, and providers. For patients with generalized myasthenia gravis (gMG), SDM helps navigate complex treatment decisions while aligning care with individual preferences and values. This is particularly critical in gMG due to its diverse symptom burden and evolving therapeutic landscape.

Studies show that SDM improves decision quality, enhances patient autonomy, and reduces decisional regret. Tools like the SHARE approach guide providers through key steps: engaging patients, comparing treatment options, assessing values, making joint decisions, and evaluating outcomes.

Despite its benefits, barriers such as time constraints, inadequate patient education, and limited provider training often hinder SDM adoption. To overcome these challenges, interventions like decision aids and patient activation strategies have shown promise. While no single approach has been proven superior, training programs like the SDM-N scale can enhance provider competency and improve care quality.

In gMG management, SDM also promotes effective care coordination by facilitating communication between specialists, such as neurologists, and generalists, including PCPs, NPs, and PAs. This collaboration ensures that all members of the care team are aligned on treatment goals, enabling comprehensive, patient-centered care. By embracing SDM, providers can empower gMG patients to actively participate in their treatment, fostering better outcomes and stronger patient-provider relationships.

How do you integrate SDM into your gMG treatment planning? What strategies or frameworks have you found most effective in supporting patient involvement?

Show More Comments

  • Saved
Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis - PubMed

Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41264893/

This large cohort study highlights distinct clinical and prognostic differences in MG by age at onset. Pubertal-onset juvenile MG and late-onset MG represent vulnerable groups, with late-onset MG demonstrating poorer...

Multicenter retrospective study comparing clinical features and outcomes across juvenile, early-onset, and late-onset MG. Pubertal-onset and late-onset groups showed higher risks and poorer treatment response, identifying vulnerable subpopulations.

  • Saved
The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review - PubMed

The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41243030/

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating muscle weakness due to antibody-mediated impairment of acetylcholine receptor (AChR) function. Traditionally, MG has been...

This review outlines diverse non-motor manifestations in myasthenia gravis, including autonomic, cognitive, psychiatric, sensory, gastrointestinal, cardiovascular, and sleep disturbances, highlighting underlying mechanisms and emphasizing multidisciplinary assessment to improve outcomes.

  • Saved
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis - PubMed

Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39426360/

The clinical benefit of efgartigimod was sustained over repeat treatment cycles and maintained over the long term. Response to treatment was consistent regardless of response definition and was repeated in...

Post-hoc analyses of ADAPT and ADAPT+ trials show sustained, robust, and repeatable clinical benefits of efgartigimod in AChR-Ab+ generalized myasthenia gravis, with consistent response rates across definitions, disease duration, and prior therapy exposure.

  • Saved
American Association of Neuromuscular & Electrodiagnostic Medicine Summary

The 2025 annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) took place in San Francisco from Oct. 29 to Nov. 1, 2025. Spanning four days, the meeting brought together physicians, technologists, advanced practice providers, and other health care professionals to learn more about the latest advances in neuromuscular medicine, electrodiagnostic medicine, and neuromuscular ultrasound, including the rapidly evolving landscape for treating myasthenia gravis. 

Click above for an exclusive summary of this year's conference!